Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 5/20 | 0.35 |
| ▸ | LITAF | Q99732 | 5/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887195 | 1.00 | PDE4B (0.39) | PDE4BPDE4DPDE4APDE4CPKM | |
| SCHEMBL4883295 | 0.91 | JAK2 (0.39) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4883291 | 0.91 | JAK2 (0.39) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4870413 | 0.90 | PDE4B (0.40) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4870421 | 0.90 | PDE4B (0.40) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4886119 | 0.89 | PDE4B (0.39) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4886115 | 0.89 | PDE4B (0.39) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4879091 | 0.88 | PDE4B (0.38) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4879150 | 0.88 | PDE4B (0.38) | PDE4BPDE4DPDE4APDE4CTNF | |
| SCHEMBL4879164 | 0.88 | PDE4B (0.38) | PDE4BPDE4DPDE4APDE4CTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227797-A1 | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | claimed |
| US-20080227797-A1 | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227797-A1 | Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases | PDE4A, PDE4B, PDE5A | PDE4B 2/4885PDE4D 7/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.